Simplex Trading’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $386K | Sell |
83,251
-749
| -0.9% | -$1.94K | ﹤0.01% | 3932 |
|
|
2026
Q1 | $234K | Buy |
84,000
+78,421
| +1,406% | +$239K | ﹤0.01% | 4115 |
|
|
2025
Q4 | $23.2K | Sell |
5,579
-61,761
| -92% | -$325K | ﹤0.01% | 6340 |
|
|
2025
Q3 | $285K | Buy |
67,340
+22,646
| +51% | +$85.2K | ﹤0.01% | 4523 |
|
|
2025
Q2 | $94K | Buy |
44,694
+43,915
| +5,637% | +$65.7K | ﹤0.01% | 5298 |
|
|
2025
Q1 | $0 | Sell |
779
-17,205
| -96% | -$24.1K | ﹤0.01% | 8870 |
|
|
2024
Q4 | $23K | Buy |
17,984
+8,194
| +84% | +$19.6K | ﹤0.01% | 6568 |
|
|
2024
Q3 | $26K | Sell |
9,790
-1,564
| -14% | -$3.84K | ﹤0.01% | 6465 |
|
|
2024
Q2 | $25K | Buy |
11,354
+3,477
| +44% | +$10.6K | ﹤0.01% | 6704 |
|
|
2024
Q1 | $18K | Buy |
7,877
+917
| +13% | +$1.74K | ﹤0.01% | 7169 |
|
|
2023
Q4 | $11K | Sell |
6,960
-3,737
| -35% | -$7.25K | ﹤0.01% | 7361 |
|
|
2023
Q3 | $20K | Buy |
10,697
+1,883
| +21% | +$3.1K | ﹤0.01% | 6617 |
|
|
2023
Q2 | $12K | Buy |
8,814
+817
| +10% | +$1.39K | ﹤0.01% | 7233 |
|
|
2023
Q1 | $16K | Sell |
7,997
-11,726
| -59% | -$18.9K | ﹤0.01% | 7127 |
|
|
2022
Q4 | $22K | Buy |
19,723
+9,293
| +89% | +$12.4K | ﹤0.01% | 6775 |
|
|
2022
Q3 | $17K | Sell |
10,430
-17,441
| -63% | -$32.6K | ﹤0.01% | 7677 |
|
|
2022
Q2 | $36K | Buy |
27,871
+14,930
| +115% | +$21.5K | ﹤0.01% | 6913 |
|
|
2022
Q1 | $20K | Buy |
12,941
+8,635
| +201% | +$16.7K | ﹤0.01% | 8251 |
|
|
2021
Q4 | $8K | Buy |
+4,306
| New | +$12.3K | ﹤0.01% | 9189 |
|
|
2021
Q2 | – | Sell |
-3,910
| Closed | -$13.9K | – | 10243 |
|
|
2021
Q1 | $8K | Buy |
3,910
+3,851
| +6,527% | +$8.63K | ﹤0.01% | 8013 |
|
|
2020
Q4 | $0 | Buy |
+59
| New | +$155 | ﹤0.01% | 8567 |
|
|
2020
Q2 | – | Sell |
-1,744
| Closed | -$4.39K | – | 7842 |
|
|
2020
Q1 | $3K | Buy |
+1,744
| New | +$4.24K | ﹤0.01% | 7051 |
|
|
2019
Q3 | – | Sell |
-986
| Closed | -$3.56K | – | 7449 |
|
|
2019
Q2 | $4K | Buy |
+986
| New | +$4.27K | ﹤0.01% | 6531 |
|
|
2019
Q1 | – | Sell |
-7,727
| Closed | -$37.1K | – | 7338 |
|
|
2018
Q4 | $26K | Buy |
7,727
+4,208
| +120% | +$20.1K | ﹤0.01% | 5123 |
|
|
2018
Q3 | $21K | Buy |
+3,519
| New | +$19.4K | ﹤0.01% | 5918 |
|
|
2018
Q2 | – | Sell |
-1,315
| Closed | -$6.41K | – | 7524 |
|
|
2018
Q1 | $6K | Sell |
1,315
-3,695
| -74% | -$17.2K | ﹤0.01% | 4471 |
|
|
2017
Q4 | $16K | Sell |
5,010
-23,677
| -83% | -$59.9K | ﹤0.01% | 3501 |
|
|
2017
Q3 | $61K | Buy |
+28,687
| New | +$56.8K | ﹤0.01% | 2127 |
|
|
2016
Q3 | – | Sell |
-8,483
| Closed | -$15.1K | – | 5999 |
|
|
2016
Q2 | $12K | Sell |
8,483
-498
| -6% | -$731 | ﹤0.01% | 3409 |
|
|
2016
Q1 | $12K | Buy |
8,981
+702
| +8% | +$943 | ﹤0.01% | 3295 |
|
|
2015
Q4 | $13K | Buy |
8,279
+8,229
| +16,458% | +$18.8K | ﹤0.01% | 3072 |
|
|
2015
Q3 | $0 | Buy |
+50
| New | +$118 | ﹤0.01% | 5719 |
|
|
2015
Q2 | – | Sell |
-2,274
| Closed | -$6.86K | – | 5386 |
|
|
2015
Q1 | $7K | Sell |
2,274
-4,829
| -68% | -$17.3K | ﹤0.01% | 3214 |
|
|
2014
Q4 | $25K | Buy |
+7,103
| New | +$31.4K | ﹤0.01% | 1881 |
|
Other funds holding GALT
WANY
Simplex Trading's GALT Position: Q2 2026 in Review
Simplex Trading reduced its Galectin Therapeutics (GALT) stake by 0.89% in Q2 2026, selling an estimated $1.94K and leaving 83,251 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #3932.
Simplex Trading first reported a position in GALT in Q4 2014 and has held it in 34 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Simplex Trading held 83,251 shares of Galectin Therapeutics worth $386K as of Q2 2026.
- Simplex Trading sold 749 Galectin Therapeutics shares in Q2 2026, an estimated $1.94K.
- Galectin Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #3932 holding.
- Simplex Trading first reported a position in Galectin Therapeutics in Q4 2014 and has held it in 34 quarters since.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.